drugset
drugset / Trial / NCT05455502

A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-548

NCT05455502 ↗

Phase 1 Completed 24 enrolled Vertex Pharmaceuticals Incorporated
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the relative bioavailability and food effect of a new tablet formulation of VX-548 in healthy adult participants.

Timeline

Start
2022-07-13
Primary completion
2022-09-17
Completion
2022-09-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Suzetrigine Small molecule — Oral

Indications

No indication recorded.